ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.18 by $0.26. The specialty pharmaceutical company had revenue of $54.36 million for the quarter, compared to analysts' expectations of $55.20 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.13 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals updated its FY19 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of $5.57-6.21 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.01. The company issued revenue guidance of $220-226 million, compared to the consensus revenue estimate of $239.80 million.

4 brokers have issued twelve-month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $76.00 to $90.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $84.25 in the next year. This suggests a possible upside of 13.0% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

Media headlines about ANIP stock have trended somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for ANI Pharmaceuticals.

ANI Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,490,000 shares, an increase of 19.2% from the August 30th total of 1,250,000 shares. Based on an average daily volume of 154,900 shares, the days-to-cover ratio is currently 9.6 days. Currently, 16.3% of the company's stock are sold short. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Emergent Biosolutions (EBS), Alkermes (ALKS), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE) and Arena Pharmaceuticals (ARNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), Micron Technology (MU), Alibaba Group (BABA), Celgene (CELG), NVIDIA (NVDA), NXP Semiconductors (NXPI) and Skyworks Solutions (SWKS).

ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Regent Investment Management LLC (0.33%), State of Alaska Department of Revenue (0.06%), Nwam LLC (0.06%), Campbell & CO Investment Adviser LLC (0.05%), Nisa Investment Advisors LLC (0.03%) and Robeco Institutional Asset Management B.V. (0.01%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Nwam LLC. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Campbell & CO Investment Adviser LLC, Robeco Institutional Asset Management B.V. and Regent Investment Management LLC. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $74.59.

ANI Pharmaceuticals has a market capitalization of $902.54 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]